INmune Bio Inc.: Business Overview, Financials & Competitive Analysis
INmune Bio Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Clinical-stage biotech with promising multi-platform approach but challenged by trial failures, mounting losses, and clinical-stage execution risks. Losses increased to $42.08 million in 2024 (40.2% higher than 2023), and the experimental Alzheimer's drug (XPro) failed to meet primary endpoints in the Phase 2 MINDFuL trial, representing a significant setback.
What is INmune Bio Inc.'s industry? INmune Bio Inc. (inmunebio.com) operates in Clinical-Stage Biotechnology / Immunotherapy. AskCyborg classifies INmune Bio Inc. under Clinical-Stage Biotechnology / Immunotherapy in its company registry.
INmune Bio is a clinical-stage immunology company focused on developing drugs to reprogram the patient's innate immune system to treat hematologic malignancies, solid tumors, and chronic inflammation. The company oper...
Cyborg Score thesis
Clinical-stage biotech with promising multi-platform approach but challenged by trial failures, mounting losses, and...
Read the full analyst-debate transcript →Get the Latest INmune Bio Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeINmune Bio Inc. Overview
Pro stress-test →INmune Bio is a clinical-stage immunology company focused on developing drugs to reprogram the patient's innate immune system to treat hematologic malignancies, solid tumors, and chronic inflammation. The company operates three distinct product platforms targeting unmet needs in oncology, neurodegenerative diseases, and inflammatory conditions.
Strategic Profile
Pro stress-test →The Dominant-Negative TNF (DN-TNF) Platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor (sTNF) without interfering with trans-membrane TNF or TNF receptors. Key development programs include INKmune (Phase 1 for high-risk myelodysplastic syndrome), INB03 (Phase II for breast cancer), and XPro1595 (for Alzheimer's disease and treatment resistant depression).
Competitive Landscape
Pro stress-test →INmune Bio is a publicly traded clinical-stage biotechnology company competing in the immunotherapy space against larger established players and other clinical-stage biotech firms. The company's precision medicine approach targeting innate immune dysfunction differentiates it from broader immunotherapy platforms, though it faces intense competition from well-capitalized CAR-T and checkpoint inhibitor developers.
Industry Context
INmune Bio Inc. operates in Clinical-Stage Biotechnology / Immunotherapy.
Key facts
Founded: 2015 · Headquarters: Boca Raton, Florida · Revenue: $14,000 (2024)